RZLT Rezolute Inc.

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

$12.40
As of 02/23/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA

05/13/2013
8,352,277
7,409
$103,902,326
0.00%
SEC Edgar Online
10-Q
10-K



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
2.89
0.00
-53.79%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy